Personalis (NASDAQ:PSNL) Shares Up 13.5% – Still a Buy?

Personalis, Inc. (NASDAQ:PSNL) shot up 13.5% during mid-day trading on Monday . The stock traded as high as $6.88 and last traded at $7.2180. 332,325 shares were traded during trading, a decline of 80% from the average session volume of 1,650,960 shares. The stock had previously closed at $6.36.

Wall Street Analyst Weigh In

PSNL has been the topic of a number of research analyst reports. Guggenheim raised their target price on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Needham & Company LLC upped their price target on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. BTIG Research lowered their price target on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Morgan Stanley dropped their price objective on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Personalis presently has an average rating of “Moderate Buy” and an average price target of $11.00.

Personalis Stock Performance

The company’s 50 day moving average is $6.61 and its 200 day moving average is $8.09. The stock has a market capitalization of $698.59 million, a price-to-earnings ratio of -6.55 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million. On average, equities research analysts anticipate that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Institutional Trading of Personalis

Institutional investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. increased its stake in Personalis by 273.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after acquiring an additional 7,896,714 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Personalis by 1,332.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after acquiring an additional 1,347,439 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after purchasing an additional 1,281,695 shares in the last quarter. Aberdeen Group plc increased its stake in shares of Personalis by 36.1% in the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after buying an additional 861,948 shares during the period. Finally, ARK Investment Management LLC raised its holdings in Personalis by 11.3% during the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.